CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin Product Description — Research Use Only
CJC-1295 + Ipamorelin is a research peptide blend commonly studied for growth hormone signaling, IGF-1 pathway activity, pituitary response, recovery-related pathways, fat-metabolism research, and body-composition markers. CJC-1295 is a GHRH analog, while Ipamorelin is a growth hormone secretagogue studied for activity at the ghrelin/GHSR receptor pathway.
Research on this blend most commonly focuses on growth hormone release, GH pulse signaling, IGF-1 activity, recovery response, protein-balance pathways, fat metabolism, and tissue-maintenance research. Published studies describe CJC-1295 as a long-acting GHRH analog associated with increased GH and IGF-1 activity, while Ipamorelin has been described as a selective growth hormone secretagogue that stimulates GH release through a GHRP-like receptor pathway.
CJC-1295 + Ipamorelin is commonly studied for:
Growth hormone signaling — how the pituitary responds to GH-releasing signals
IGF-1 pathways — how GH signaling influences IGF-1-related activity
GH pulse research — how natural growth hormone release patterns are studied
Recovery response — pathways connected to repair, restoration, and rebuilding
Muscle-support pathways — research involving protein balance and tissue maintenance
Fat metabolism — pathways connected to how stored energy is processed
Body-composition research — markers related to lean mass, fat mass, and energy balance
CJC-1295 + Ipamorelin is commonly studied because the two peptides act through related but different GH-axis pathways. CJC-1295 supports GHRH-like signaling, while Ipamorelin is studied as a ghrelin mimetic/GHSR-related secretagogue with GH-releasing activity. CJC-1295 research has also reported that pulsatile GH secretion may persist during continuous stimulation, making it useful in GH-pulse and pituitary-response studies.
For research use only. Not for human consumption, medical use, diagnostic use, or therapeutic application.